Key Highlights
- Amgen revealed plans for an additional $300 million capital injection into its Juncos, Puerto Rico biologics production site.
- The Puerto Rico facility serves as a distribution hub for pharmaceutical products reaching over 60 nations worldwide.
- This commitment builds upon more than $650 million in previously disclosed investments for Puerto Rico during the last twelve months.
- Across the United States, Amgen has pledged upwards of $3.65 billion in manufacturing infrastructure over the past year, spanning Puerto Rico, Ohio, California, and North Carolina locations.
- The announcement follows an executive directive from President Trump imposing potential 100% tariffs on imported branded pharmaceutical products.
Shares of Amgen (AMGN) dropped 1.54% during Monday’s trading session after the pharmaceutical manufacturer unveiled a $300 million capital commitment to enhance its biologics production operations in Juncos, Puerto Rico.
The capital allocation targets increased production capabilities and the integration of advanced manufacturing technologies at the Puerto Rico location, which has served the company since its establishment in 1992.
Currently, the Juncos manufacturing complex supplies biologic therapeutic products to more than 60 countries globally. The funding will bolster existing workforce positions at the facility while generating hundreds of temporary construction opportunities.
Chief Executive Officer Robert Bradway characterized the expansion as evidence of Amgen’s “ongoing dedication to American manufacturing” and emphasized its role in securing domestic supply networks and ensuring patient medication availability.
Puerto Rico’s Governor Jenniffer González Colón expressed appreciation for the announcement, describing the investment as validation that policies encouraging the island’s biopharmaceutical industry are yielding results.
The fresh $300 million allocation supplements the $650 million Amgen had previously committed to Puerto Rico within the last year, which was projected to generate approximately 750 employment positions.
Broader National Manufacturing Initiative
This recent pledge forms part of an extensive domestic infrastructure strategy. Throughout the past twelve months, Amgen has designated $900 million for Ohio facilities, $600 million toward a California-based science and innovation campus, and over $1.5 billion for North Carolina operations.
When combined with the latest Puerto Rico announcement, Amgen’s recent American manufacturing investments exceed $3.65 billion in aggregate value.
Following the passage of the Tax Cuts and Jobs Act in 2017, Amgen reports having directed more than $40 billion toward manufacturing facilities and research and development activities.
Tariff Environment Influences Strategy
The capital commitment arrives amid heightened scrutiny from the Trump administration regarding pharmaceutical product imports.
President Trump executed an executive order in April establishing 100% tariffs on branded pharmaceutical imports entering American markets, with exemptions available for manufacturers accepting government pricing agreements or pledging domestic production operations.
Amgen’s broadened domestic manufacturing presence enables the organization to address these regulatory dynamics, although company officials presented the Puerto Rico initiative as aligned with long-term supply chain objectives.
Puerto Rico, operating as a U.S. territory, has functioned as a pharmaceutical manufacturing center for more than six decades and hosts numerous major pharmaceutical corporation facilities.
The Juncos location has operated within Amgen’s production network since 1992 and maintains a critical function in the company’s international biologics distribution system.
Amgen has yet to announce a definitive completion schedule for the Puerto Rico expansion project.
